Download presentation
1
Stephen Ko, M.D. Mayo Clinic Jacksonville
Post-operative Radiation Therapy following Radical Prostatectomy for Prostate Cancer Stephen Ko, M.D. Mayo Clinic Jacksonville
2
Prostate Cancer One third of patients undergo radical prostatectomy as initial therapy 25-33% of patients are at risk of treatment failure following radical prostatectomy 60-70% will develop metastatic disease within 10 years without further treatment
3
Post-operative Radiation Therapy following Radical Prostatectomy
Adjuvant radiotherapy – presence of adverse factors – undetectable PSA Salvage Radiotherapy – rising PSA Salvage Radiotherapy – clinically apparent recurrent tumor in the prostatic fossa
4
Adjuvant Radiation Therapy Rationale
Residual disease in the prostatic fossa is the primary cause of treatment failure A substantial number of cells may be present before PSA is detectable Greatest opportunity for cure exists when the cells are fewest in number and localized
5
Adjuvant Radiation Therapy Declining in Utilization
12% 7%
6
Adjuvant Radiation Therapy Pathologic Indications
Extraprostatic extension Seminal Vesicle invasion Positive Surgical Margins
7
Adjuvant Radiation Therapy Prospective Randomized Clinical Trials
Study No. Years Patients SWOG EORTC ARO
8
Adjuvant Radiation Therapy Eligibility
SWOG EORTC ARO Exraprostatic extension + S.V. + Margins Undetectable PSA
9
Adjuvant Radiation Therapy Endpoints
SWOG EORTC ARO Biochemical Relapse Free survival Local Relapse Metastasis Free Survival Overall Survival
10
Adjuvant Radiation Therapy Results
Freedom Biochemical from Relapse Local Control RP RP+RT Actuarial Endpoint ARO 54 72* NS 5 yrs EORTC 53 74* 85 95* SWOG 44 78 92* 25 51* 10 yrs *Statistically significant with RT All numbers are in percentages
11
Adjuvant Radiation Therapy Results
Clinical Free Disease Survival Metastasis Survival Overall RP RP+RT Actuarial Endpoint ARO NS 95 97 5 yrs EORTC 81 91* 94 93 92 SWOG 70 84* 82 87 90 91 49 70* 61 71* 66 74* 10 yrs *Statistically significant with RT All numbers are in percentages
12
Radical Prostatectomy Adjuvant Androgen Suppression
Study Outcome + Pelvic Lymph Nodes Messing Prospective Randomized Improved Survival +S.V., +Margins, Extracapsular extension RTOG 8531 – Subset Analysis MRC PR 10 Accruing EORTC
13
Post-operative Radiation Therapy following Radical Prostatectomy
Adjuvant radiotherapy – presence of adverse factors – undetectable PSA Salvage Radiotherapy – rising PSA Salvage Radiotherapy – clinically apparent recurrent tumor in the prostatic fossa
14
Salvage Radiotherapy PSA Serum Half-Life = 3.1 days
PSA should be undetectable > 4 weeks after RP Biochemical Relapse AUA > 0.2, twice consecutively Stephenson > 0.4, twice consecutively
15
Radical Prostatectomy: Biochemical Relapse Factors Associated with Metastatic Disease and Death
Persistently elevated PSA after Prostatectomy Shorter interval from surgery to biochemical relapse Shorter PSA doubling time Higher Gleason Scores Higher GPSM Scores Non-diploid tumor DNA
16
Radical Prostatectomy GPSM Scoring Algorithm
GPSM – Prostatectomy Gleason Score + 1 (Pre-op PSA 4-10) + 2 (Pre-op PSA ) + 3 (Pre-op PSA >20) + 2 (+S.V. or +Nodes) + 2 (Positive Surgical Margins) GPSM score of >10: Increased biochemical relapse; Increased risk of death
17
GPSM Scoring Outcomes
18
Radical Prostatectomy: Post-op PSA kinetics (doubling time)
PSA Working Group Guidelines for PSAdt calculations >3 PSA values which are >0.2 ng/ml and increasing within 12 months Stable testosterone levels (not recovering from androgen suppression) Relationship of PSAdt clinical relapse and mortality – continuum
19
Radical Prostatectomy: PSA doubling time
Strongly associated with clinical relapse PSAdt <3 months: Short life expectancy PSAdt <12 months: 50-75% of patients with clinical relapse within 10 years PSAdt <15 months: 90% deaths due to prostate cancer PSAdt >15 months: 33% deaths due to prostate cancer
20
Radical Prostatectomy: Biochemical Relapse
Abnormal CT is rare with: PSA < 5-10 ng/ml PSAdt > 6-10 months Abnormal bone scan is rare with: PSA < 10 ng/ml
21
Radical Prostatectomy: Biochemical Relapse – MRI findings
Sensitivity Specificity Accuracy Endorectal MR % % % Local Recurrence averaged 1.5 cm in diameter Patients typically had PSA levels > 2 ng/ml
22
Biochemical Relapse MRI sites of Recurrence
Vesicourethral anastomosis: 44% Retrovesicle space: 30% Seminal vesicle region: 23%
23
Biochemical Relapse: Salvage Prostate Bed Radiation Therapy Results
Author Pt., No. Salvage RT Dose Median (Gy) Biochemical Response % BCR-free% Endpoint actuarial Neuhof 171 63.0 83 35 5-yr Ward 211 64.0 90 48-66 5-yr. Brooks 114 69 33 6-yr. Stephenson 1540 64.8 59 32 Maier 170 68.0 - 44 7-yr. Buskirk 368 30 8-yr. Pazona 223 73 25 10-yr.
24
Salvage Prostate Bed Radiation Therapy Prognostic Factors
Prostatectomy Gleason Score Tumor DNA ploidy Persistently detectable post-op PSA PSA level before prostatectomy PSAdt postoperatively Surgical Margin status Seminal vesicle invasion Pelvic lymph node involvement Delay in initiation of salvage RT
25
Salvage Prostate Bed Radiation Therapy Prognostic Scoring Systems
Stephenson Nomogram Mayo Scoring System
26
Stephenson Nomogram
27
Stephenson Algorithm
28
Mayo Scoring System
29
Mayo Scoring System Points y BCR % 2 53% 3 26% %
30
Dose Response Analysis
31
Dose Response PSA <0.6
32
Dose Response >0.6
33
Salvage Radiation Therapy +/- Androgen Suppression
RTOG 9601 – Prostate fossa RT + placebo RT + bicalutamide RTOG 0534 Prostate fossa RT Prostate fossa RT with androgen suppression Prostate fossa + Node RT with androgen suppression Japan Clinical Oncology Group 0401 Prostate fossa RT + bicalutamide Medical Research Council PR 10 Prostate fossa RT + 6 months androgen suppression Prostate fossa RT + 2 years androgen suppression
34
Salvage Radiation Therapy Consensus Based Guidelines
Organizations which support offering salvage RT to all men with a detectable PSA NCCN European Association of Urology European Society of Medical Oncology Australian and New Zealand Radiation Oncology Genito-Urinary Group
35
Post-operative Radiation Therapy following Radical Prostatectomy
Adjuvant radiotherapy – presence of adverse factors – undetectable PSA Salvage Radiotherapy – rising PSA Salvage Radiotherapy – clinically apparent recurrent tumor in the prostatic fossa
36
Radical Prostatectomy Clinically-Apparent Local Recurrence
Author Pt, No. RT Dose Median (Gy) Local control % BCR-free% Actuarial Endpoint Koppie 34 68.4 - 39 3 yrs Cadeddu 25 64.0 14 5 yrs Choo 44 63.0 97 11 Macdonald 42 95 27 Wiegal 20 65.0 68 vander Kooy 35 56 8 yrs Syndikus 26 52.0 54 10 yrs
37
RTOG guidelines salvage RT
38
Positive apical margin + bCR
39
ECE + SVI
40
Dose Constraints Rectum Bladder Femori Comments RTOG 0534 V40<45%
Rectum:rectosigmoid junction ischium; bladder: entire; femori: head intertrochanter Cozzarrini V50<63% V55<57% V60<50% - Rectum: rectosigmoid junction anal verge Fonteyne V40<84% V50<68% V60<59% V65<48% Rectal wall: 0.6 cm superior to target volume inferiorly Sidhom V60<40% Rectum: rectosigmoid junction 1.5 cm inferior of CTV
41
Post-op Prostate Bed Radiation Therapy Adverse Effects
Early: During RT or within 90 days of RT completion Late: Effects which occur or persist after 90 days of RT completion
42
Post-op Prostate Bed Radiation Therapy Adverse Effects
Prognostic Factors Antecedent Surgery RT Treatment Planning RT Treatment Techniques RT Dose Volumetric Perimeters Imaging and localization methods
43
Post-op Prostate Bed Radiation Therapy Early Adverse Effects
Dysuria Urgency/Frequency Proctalgia Increased daily stools Hematochezia
44
Post-op Prostate Bed Radiation Therapy Early Adverse Effects
Prognostic Factors Rectal dose Pelvic nodal RT Diabetes Mellitus Hemorrhoids Androgen Suppression Anticoagulant Use
45
Post-op Prostate Bed Radiation Therapy Late Adverse Effects
Late grade >2 adverse events is <20% at 5 years Prevalence is considerably less as many adverse events are not chronic Severe events are <1%
46
Post-op Prostate Bed Radiation Therapy Late Adverse GI Effects
Increased or urgent stools/tenesmus Proctalgia Hematochezia Mucous discharge Rectal stricture Fecal incontinence (0.2%) Five-year incidence of >2 GI events is <5% Severe GI events are uncommon <1%
47
Post-op Prostate Bed Radiation Therapy Late Adverse GU Effects
Difficult to accurately attribute late GU effects causality because both surgery and RT contribute Incidence of grade >2 late effects is approximately 10% Bladder Neck Contracture Urethral stricture 5% Dysuria Transient hemturia (5%)
48
Post-op Prostate Bed Radiation Therapy Late Adverse GU Effects
Urinary incontinence is comparable to surgery alone If urinary incontinence occurs, it is typically of mild, stress-induced nature RT does not appear to diminish erectile dysfunction in men who undergo nerve-sparing prostatectomy
49
Post-op Prostate Bed Radiation Therapy –Late Side Effects
Mayo Clinic Jacksonville Retrospectively reviewed 308 patients who received salvage radiation therapy for a detectable PSA after prostatectomy Aim: Evaluate the nature and severity of late GI and GU toxicity associated with salvage radiation therapy
50
Post-op Prostate Bed Radiation Therapy –Late Side Effects
Mayo Clinic Jacksonville GU toxicity Grade 2: 7.7% Grade 3-4: 1% Included 3 patients with cystitis 14 of 18 patients who developed urethral strictures required dilatation 3.4% of patients had worsening urinary control
51
Post-op Prostate Bed Radiation Therapy –Late Side Effects
Mayo Clinic Jacksonville GI toxicity Grade 2: 1.3% Grade 3-4: 0.3% Included one patient that required a diverting colostomy
52
Comparison of Late GI Toxicity
Pro/Retrospective Adjuvant/Salvage Trials # pts. F/U mths. Grade 2 Grade 3 Grade 4 Our results 308 61 1.3% 0% 0.3% Bolla et al. EORTC 22911 1005 45 2.5% Thompson et al. SWOG 8794 214 127 3.3% Feng et al. 959 55 4% 0.4% Zelefsky et al. 42 24 5% Choo et al. 98 50 Forman et al. 16 -
53
Post-op Prostate Bed Patient Reported Quality of Life
Pinkawa et al. (Modern salvage RT technology) Reduced urinary frequency and bother only at end of RT Reduced bowel function and bother was reported through 2 months, but not thereafter
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.